Holen Sie sich die Stockscreener-App
18.50
4.23%
0.75
Vorhandelsmarkt:
18.04
-0.46
-2.49%
Schlusskurs vom Vortag:
$17.75
Offen:
$17.21
24-Stunden-Volumen:
1.30M
Relative Volume:
0.85
Marktkapitalisierung:
$1.41B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-8.2589
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
-5.18%
1M Leistung:
-11.40%
6M Leistung:
+276.02%
1J Leistung:
+236.36%
1-Tages-Spanne:
$17.04
$18.73
1-Wochen-Bereich:
$17.04
$20.41
52-Wochen-Spanne:
$3.5001
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
18.50 | 1.35B | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Therapeutics advances MRT-2359 into Phase 2 trial targeting AR mutations in mCRPC - Traders Union
Insider Sell: Filip Janku Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
Monte Rosa shares rise on prostate cancer trial results By Investing.com - Investing.com South Africa
Monte Rosa shares rise on prostate cancer trial results - Investing.com
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASC - The Manila Times
Monte Rosa Therapeutics Presents Updated Clinical Data from - GlobeNewswire
Biotech firm Monte Rosa lines up three investor talks in March - Stock Titan
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Does Monte Rosa Therapeutics Inc have pricing power2025 Buyback Activity & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
What are Monte Rosa Therapeutics Inc.’s recent SEC filings showingWeekly Stock Recap & Stock Portfolio Risk Management - mfd.ru
Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by GSA Capital Partners LLP - MarketBeat
Is Monte Rosa Therapeutics Inc. stock a top pick in earnings seasonAnalyst Downgrade & Weekly Momentum Picks - mfd.ru
Portfolio Recap: Can Atomera Incorporated scale operations efficientlyEarnings Miss & Consistent Income Trade Ideas - baoquankhu1.vn
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update - MarketBeat
The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26% - simplywall.st
Does Monte Rosa Therapeutics Inc. have pricing power2025 Retail Activity & Free Community Consensus Stock Picks - mfd.ru
Is Monte Rosa Therapeutics Inc. forming a bullish divergenceWeekly Trade Summary & AI Based Buy/Sell Signal Reports - mfd.ru
Monte Rosa Therapeutics, Inc. Announces Executive Changes, Effective April 3, 2026 - marketscreener.com
Smart Money: How sensitive is Monte Rosa Therapeutics Inc to inflationEarnings Growth Report & Technical Buy Zone Confirmations - baoquankhu1.vn
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher - Investing.com
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains - Yahoo Finance
Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Spikes: Is Monte Rosa Therapeutics Inc stock a good pick for beginnersBuy Signal & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Drop in Short Interest - MarketBeat
Winners Losers: Can Monte Rosa Therapeutics Inc ride the EV waveWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Is Monte Rosa Therapeutics Inc. subject to activist investor interestPortfolio Profit Report & Daily Entry Point Trade Alerts - mfd.ru
Promising Small Cap Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6.9%What's Next? - MarketBeat
Aug Volume: What are Monte Rosa Therapeutics Incs earnings expectationsIPO Watch & Detailed Earnings Play Strategies - baoquankhu1.vn
Aug Gainers: Is Monte Rosa Therapeutics Inc stock a hidden gemJuly 2025 Earnings & Weekly High Potential Stock Alerts - baoquankhu1.vn
51,133 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Biotech Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Monte Rosa Therapeutics announces pricing of $300M stock offering - MSN
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 20.7% - MarketBeat
Goodwin Guides Monte Rosa Therapeutics In Pricing Of $300 Million Underwritten Public Offering - Mondaq
The Bull Case For Monte Rosa Therapeutics (GLUE) Could Change Following MRT-8102 Data And $300 Million Raise - Sahm
Monte Rosa Therapeutics (GLUE) Price Target Increased by 30.77% to 28.49 - Nasdaq
Aug Highlights: Does Monte Rosa Therapeutics Inc stock trade at a discount to peersWeekly Trend Report & High Return Stock Watch Alerts - Bộ Nội Vụ
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum - Yahoo Finance
How institutional buying supports Monte Rosa Therapeutics Inc. stockJuly 2025 Highlights & Daily Market Momentum Tracking - Улправда
Latham & Watkins Advises on Monte Rosa Therapeutics’ US$300 Million Underwritten Public Offering - Latham & Watkins LLP
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares - MarketBeat
Monte Rosa Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler - TradingView — Track All Markets
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Monte Rosa Therapeutics down after increased $300 mln equity raise - TradingView
Monte Rosa Therapeutics Prices Underwritten Public Offering Of $300 Mln Of Shares - Nasdaq
Why Monte Rosa Therapeutics Inc. stock is considered a top pickWeekly Investment Recap & Risk Managed Investment Strategies - ulpravda.ru
Monte Rosa Therapeutics prices $300 million public offering By Investing.com - Investing.com South Africa
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.90%
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):